Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: Outcomes before and after 2006

M. A. Gertz, M. Q. Lacy, A. Dispenzieri, S. K. Kumar, F. K. Buadi, D. Dingli, N. Leung, W. J. Hogan, S. R. Hayman

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

The role of auto-SCT in the management of Ig light-chain (AL) amyloidosis remains undefined. In this study, we report 422 patients who received auto-SCT for AL amyloidosis to compare outcomes of patients treated before January 2006 with those treated from January 2006 to 1 December 2009. Day 100 all-cause mortality decreased over this time period from 12 to 7% (P0.09). Survival at 2 years increased from 78 to 82%. The major determinants of early mortality (before day 100) were the presence of cardiac involvement by amyloid with increased levels of cardiac biomarkers, lower serum albumin, higher serum creatinine and a higher number of organs involved. On multivariate survival analysis, higher levels of serum troponin T and N-terminal pro-brain natriuretic peptide were the only predictors of early mortality after auto-SCT. Improved supportive care and refined patient selection have improved the safety margin of patients undergoing auto-SCT; short-term mortality showed a more than 40% decrease after 2005.

Original languageEnglish (US)
Pages (from-to)970-975
Number of pages6
JournalBone Marrow Transplantation
Volume46
Issue number7
DOIs
StatePublished - Jul 1 2011

Keywords

  • amyloidosis
  • auto-SCT
  • cardiac failure
  • chemotherapy
  • survival

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: Outcomes before and after 2006'. Together they form a unique fingerprint.

  • Cite this